Dose-response study of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinaemia

      This paper is only available as a PDF. To read, Please Download here.


      The effect of bezafibrate in the dosages 450, 900 and 1350 mg daily on serum lipoprotein concentrations were studied in 20 subjects with primary hyperlipoproteinaemia (16 of type IV, 2 of type II B, 1 of type III). Except for LDL cholesterol maximum effects were obtained with 450 mg daily. Total serum cholesterol and triglycerides (TG) fell significantly. Mean very low density lipoprotein (VLDL) TG fell by 54%. The maximum effect on low density lipoprotein was obtained with 900 mg daily. The effect was highly dependent on initial concentrations, decreases being observed above 4 mmoles/1 and increases below that concentration. High density lipoprotein cholesterol increased by 31% (P < 0.01) independently of the VLDL decrease. Three subjects suffered gastrointestinal side-effects on 1350 mg daily. Only benign reversible changes were noted on non-lipid measurements. Bezafibrate is a well-tolerated drug with a good VLDL TG lowering effect. It is particularly effective in increasing HDL cholesterol concentrations.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Olsson A.G.
        • Rössner S.
        • Walldius G.
        • Carlson L.A.
        • Lang P.D.
        Effect of BM 15.075 on lipoprotein concentrations in different types of hyperlipoproteinaemia.
        Atherosclerosis. 1977; 27: 279-287
        • Block W.D.
        • Jarrett K.J.
        • Leoine B.
        Use of a single color reagent to improve the automated determination of serum total cholesterol.
        in: 3rd edition. Automation in Analytical Chemistry. Vol. 1. Mediad Inc, New York, NY1965: 345
        • Kessler G.
        • Lederer H.
        Fluorimetric measurements of triglycerides.
        in: 3rd edition. Automation in Analytical Chemistry. Vol. 1. Mediad Inc, New York, NY1965: 341
        • Carlson K.
        Lipoprotein fractionation.
        J. Clin. Path. 1973; 26 (Suppl. (Ass. Clin. Path.), 5): 32-37
        • Beaumont J.L.
        • Carlson L.A.
        • Cooper G.R.
        • Fejfar Z.
        • Fredrickson D.S.
        • Strasser T.
        Classification of hyperlipidaemias and hyperlipoproteinaemias.
        Bull. Wld Hlth Org. 1970; 43: 891
        • Endele R.
        A gaschromatographic method for the determination of bezafibrate in serum and urine.
        J. Chromatogr. 1978; 154: 261-263
        • Olsson A.G.
        • Orö L.
        • Rössner S.
        Dose-response effect of single and combined clofibrate (Atromidin®) and niceritol (Perycit®) treatment on serum lipids and lipoproteins in type II hyperlipoproteinaemia.
        Atherosclerosis. 1975; 22: 91-101
        • Carlson L.A.
        • Olsson A.G.
        • Orö L.
        • Rössner S.
        • Walldius G.
        Effects of hypolipidemic regimes on serum lipoproteins.
        in: Schettler G. Weizel A. Atherosclerosis III (Proceedings of the 3rd International Symposium. Springer-Verlag, Berlin, Heidelberg, New York1974: 768-781
        • Miller N.E.
        • Miller G.J.
        High density lipoprotein and atherosclerosis.
        Lancet. 1975; 1: 1033
        • Olsson A.G.
        • Carlson L.A.
        Studies in asymptomatic primary hyperlipidaemia. Part 1 (Types of hyperlipoproteinaemias and serum lipoprotein concentrations, compositions and interrelations).
        Acta Med. Scand., Suppl. 1975; 580
        • Carlson L.A.
        • Olsson A.G.
        • Ballantyne D.
        On the rise in low density and high density lipoproteins in response to the treatment of hypertriglyceridaemia in type IV and type V hyperlipoproteinaemias.
        Atherosclerosis. 1977; 26: 603-609
      1. Adam, O., Wolfram, G., Lang, P.D. and Zöllner, N., Dosiswirkungsuntersuchung mit Bezafibrat an Patienten mit Hypercholesterinämie and Hypertriglyceridimie, Münch. Med. Wschr., In press.